Composition analysis of Compound Shenhua Tablet, a seven-herb Chinese medicine for IgA nephropathy: evaluation of analyte-capacity of the assays

Abstract

Compound Shenhua Tablet, a medicine comprising seven herbs, is employed in treating IgA nephropathy. This study aimed to meticulously analyze its chemical composition. Based on a list of candidate compounds, identified through extensive literature review pertinent to the tablet’s herbal components, the composition analysis entailed the systematic identification, characterization, and quantification of the constituents. The analyte-capacity of LC/ESI-MS-based and GC/EI-MS-based assays was evaluated. The identified and characterized constituents were quantified to determine their content levels and were ranked based on the constituents’ daily doses. A total of 283 constituents, classified into 12 distinct categories, were identified and characterized in the Compound Shenhua Tablet. These constituents exhibited content levels of 1−10 982 μg·g⁻¹, with daily doses of 0.01−395 μmol·d⁻¹. The predominant constituents, with daily doses of ≥ 10 μmol·d⁻¹, include nine organic acids (citric acid, quinic acid, chlorogenic acid, cryptochlorogenic acid, gallic acid, neochlorogenic acid, isochlorogenic acid C, isochlorogenic acid B, and linoleic acid), five iridoids (specnuezhenide, nuezhenoside G13, nuezhenidic acid, secoxyloganin, and secologanoside), two monoterpene glycosides (paeoniflorin and albiflorin), a sesquiterpenoid (curzerenone), a triterpenoid (oleanolic acid), and a phenylethanoid (salidroside). Additionally, there were 83, 126, and 55 constituents detected in the medicine with daily doses of 1-10, 0.1-1, and 0.01-0.1 μmol·d⁻¹, respectively. The combination of the LC/ESI-MS-based and GC/EI-MS-based assays demonstrated a complementary relationship in their analyte-capacity for detecting the constituents present in the medicine. This comprehensive composition analysis establishes a solid foundation for further pharmacological research on Compound Shenhua Tablet and facilitates the quality evaluation of this complex herbal medicine.

Keywords

Compound Shenhua Tablet / Composition analysis / Analyte-capacity

References

[1] Li C. Multi-compound pharmacokinetic research on Chinese herbal medicines: approach and methodology[J]. China J Chin Mater Med, 2017, 42(4): 607-617.

[2] Li C, Cheng C, Jia WW, et al. Multi-compound pharmacokinetic research on Chinese herbal medicines: identifying the medicines’ potentially therapeutic compounds and characterizing their disposition and pharmacokinetics[J]. Acta Pharm Sin, 2021, 56(9): 2426-2446.

[3] Li C, Jia WW, Yang JL, et al. Multi-compound and drug-combination pharmacokinetic research on Chinese herbal medicines[J]. Acta Pharmacol Sin, 2022, 43(12): 3080-3095.

[4] Yu X, Niu W, Wang YY, et al. Novel assays for quality evaluation of Xuebijing: quality variability of a Chinese herbal injection for sepsis management[J]. J Pharm Anal, 2022, 12(4): 664-682.

[5] Schaneberg BT, Sara Crockett, Bedir E, et al. The role of chemical fingerprinting: application to Ephedra[J]. Phytochemistry, 2003, 62(6): 911-918.

[6] Olaleye OE, Niu W, Du FF, et al. Inhibition of hepatic OATP1Bs by circulating saponins from intravenous Shenmai: potential joint precipitants of drug interactions[J]. Acta Pharmacol Sin, 2019, 40(6): 833-849.

[7] Pintusophon S, Niu W, Duan XN, et al. Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions[J]. Acta Pharmacol Sin, 2019, 40(10): 1351-1363.

[8] Lai KN, Tang SC, Schena FP, et al. IgA nephropathy[J]. Nat Rev Dis Primers, 2016, 2: 16001.

[9] Chen XM, Chen J, Chen YP, et al. Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type[J]. Chin J Integr Med, 2007, 27(2): 101-105.

[10] Li QP, Wei RB, Yang X, et al. Protective effects and mechanisms of Shenhua Tablet on toll-like receptors in rat model of renal ischemia-reperfusion injury[J]. Chin J Integr Med, 2019, 25(1): 37-44.

[11] Geng WJ, Wei RB, Liu SW, et al. Shenhua Tablet inhibits mesangial cell proliferation in rats with chronic anti-Thy-1 nephritis[J]. Biol Res, 2016, 49: 17.

[12] Li L, Zhao YS, Du FF, et al. Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves[J]. Curr Drug Metab, 2012, 13(5): 494-509.

[13] Cheng C, Du FF, Yu K, et al. Pharmacokinetics and disposition of circulating iridoids and organic acids in rats intravenously receiving Reduning Injection[J]. Drug Metab Dispos, 2016, 44(11): 1853-1858.

[14] Li MJ, Wang FQ, Huang YH, et al. Systemic exposure to and disposition of catechols derived from Salvia miltiorrhiza roots (Danshen) after intravenous dosing Danhong Injection in human subjects, rats, and dogs[J]. Drug Metab Dispos, 2015, 43(5): 679-690.

[15] Li XX, Cheng C, Wang FQ, et al. Pharmacokinetics of catechols in human subjects intravenously receiving Xuebijing injection, an emerging antiseptic herbal medicine[J]. Drug Metab Pharmacokinet, 2016, 31(1): 95-98.

[16] Cheng C, Lin JZ, Li L, et al. Pharmacokinetics and disposition of monoterpene glycosides derived from Paeonia lactiflora roots (Chishao) after intravenous dosing of antiseptic Xuebijing Injection in human subjects and rats[J]. Acta Pharmacol Sin, 2016, 37(4): 530-544.

[17] Zhang NT, Cheng C, Olaleye OE, et al. Pharmacokinetics-based identification of potential therapeutic phthalides from Xuebijing, a Chinese herbal injection used in sepsis management[J]. Drug Metab Dispos, 2018, 46(6): 823-834.

[18] Lan XF, Olaleye OE, Lu JL, et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing Lianhua Qingwen Capsule[J]. Acta Pharmacol Sin, 2021, 42(12): 2155-2172.

[19] Chu C, Qi LW, Liu EH, et al. Radix Astragali (Astragalus): latest advancements and trends in chemistry, analysis, pharmacology and pharmacokinetics[J]. Curr Org Chem, 2010, 14(16): 1792-1807.

[20] Su HF, Shaker S, Kuang Y, et al. Phytochemistry and cardiovascular protective effects of Huang-Qi (Astragali Radix)[J]. Med Res Rev, 2021, 41(4): 1999-2038.

[21] Chang XN, Chen XF, Guo YX, et al. Advances in chemical composition, extraction techniques, analytical methods, and biological activity of Astragali Radix[J]. Molecules, 2022, 27(3): 1058.

[22] Li H, Yao WF, Liu Q, et al. Application of UHPLC-ESI-Q-TOF-MS to identify multiple constituents in processed products of the herbal medicine Ligustri Lucidi Fructus[J]. Molecules, 2017, 22(5): 689.

[23] Shang ZP, Xu LL, Zhang YQ, et al. An integrated approach to reveal the chemical changes of Ligustri Lucidi Fructus during wine steaming processing[J]. J Pharm Biomed Anal, 2021, 193: 113667.

[24] Cao M, Wu J, Peng Y, et al. Ligustri Lucidi Fructus, a traditional Chinese medicine: comprehensive review of botany, traditional uses, chemical composition, pharmacology, and toxicity[J]. J Ethnopharmacol, 2023, 301: 115789.

[25] Chang YL, Xu GL, Wang XP, et al. Anti-tumor activity and linear-diarylheptanoids of herbal couple Curcumae Rhizoma-Sparganii Rhizoma and the single herbs[J]. J Ethnopharmacol, 2020, 250: 112465.

[26] Li YH, Wu YC, Li YM, et al. Review of the traditional uses, phytochemistry, and pharmacology of Curcuma wenyujin Y. H. Chen et C. Ling[J]. J Ethnopharmacol, 2021, 269: 113689.

[27] Wu P, Dong XM, Song GQ, et al. Bioactivity-guided discovery of quality control markers in rhizomes of Curcuma wenyujin based on spectrum-effect relationship against human lung cancer cells[J]. Phytomedicine, 2021, 86: 153559.

[28] Zhu B, Zhang QL, Hua JW, et al. The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz. : a review[J]. J Ethnopharmacol, 2018, 226: 143-167.

[29] Yang L, Yu H, Hou AJ, et al. A review of the ethnopharmacology, phytochemistry, pharmacology, application, quality control, processing, toxicology, and pharmacokinetics of the dried rhizome of Atractylodes macrocephala[J]. Front Pharmacol, 2021, 12: 727154.

[30] Wu LF, Wang XQ, Chen XM, et al. Chemical constituents and pharmacological activities of Radix Paeoniae Alba: research advances[J]. J Int Pharm Res, 2020, 47(3): 175-187.

[31] Yang SS, Zhang XY, Dong YQ, et al. Cleavage rules of mass spectrometry fragments and rapid identification of chemical components of Radix Paeoniae Alba using UHPLC-Q-TOF-MS[J]. Phytochem Anal, 2021, 32(5): 836-849.

[32] Jia J, Li X, Ren XY, et al. Sparganii Rhizoma: a review of traditional clinical application, processing, phytochemistry, pharmacology, and toxicity[J]. J Ethnopharmacol, 2021, 268: 113571.

[33] Lu XN, Zheng YW, Wen F, et al. Study of the active ingredients and mechanism of Sparganii Rhizoma in gastric cancer based on HPLC-Q-TOF-MS/MS and network pharmacology[J]. Sci Rep, 2021, 11: 1905.

[34] Li YK, Li Wen, Fu CM, et al. Lonicerae Japonicae Flos and Lonicerae Flos: a systematic review of ethnopharmacology, phytochemistry and pharmacology[J]. Phytochem Rev, 2020, 19(1): 1-61.

[35] Zheng SW, Liu ST, Hou AJ, et al. Systematic review of Lonicerae Japonicae Flos: a significant food and traditional Chinese medicine[J]. Front Pharmacol, 2022, 13: 1013992.

[36] Pan HQ, Zhou H, Miao S, et al. An integrated approach for global profiling of multi-type constituents: comprehensive chemical characterization of Lonicerae Japonicae Flos as a case study[J]. J Chromatogr A, 2020, 1613: 460674.

[37] Liu Y, Chen HB, Zhao YY, et al. Quantification and stability studies on the flavonoids of Radix Hedysari[J]. J Agric Food Chem, 2006, 54(18): 6634-6639.

[38] Chu C, Liu EH, Qi LW, et al. Transformation of astragalosides from Radix Astragali under acidic, neutral, and alkaline extraction conditions monitored by LC-ESI-TOF/MS[J]. Chin J Nat Med, 2014, 12(4): 314-320.

[39] Mei XD, Wang YQ, Liu ZH, et al. The chemical transformations for Radix Astragali via different alkaline wash conditions by quantitative and qualitative analyses[J]. J Pharm Biomed Anal, 2020, 185: 113164.

[40] Giddings JC. Maximum number of components resolvable by gel filtration and other elution chromatographic methods[J]. Anal Chem, 1967, 39(8): 1027-1028.

[41] Neue UD. Peak capacity in unidimensional chromatography[J]. J Chromatogr A, 2008, 1184(1-2): 107-130.

[42] Stoll DR, Li XP, Wang XL, et al. Fast, comprehensive two-dimensional liquid chromatography[J]. J Chromatogr A, 2007, 1168(1-2): 3-43.

[43] Bao LP, Li JS, Zha DQ, et al. Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-κB pathways[J]. Int Immunopharmacol, 2018, 54: 245-253.

[44] Ahad A, Ahsan H, Mujeeb M, et al. Gallic acid ameliorates renal functions by inhibiting the activation of p38 MAPK in experimentally induced type 2 diabetic rats and cultured rat proximal tubular epithelial cells[J]. Chem Biol Interact, 2015, 240: 292-303.

[45] Bai JR, Zhang YS, Tang C, et al. Gallic acid: pharmacological activities and molecular mechanisms involved in inflammation-related diseases[J]. Biomed Pharmacother, 2021, 133: 110985.

[46] Peng CC, Hsieh CL, Wang HE, et al. Ferulic acid is nephrodamaging while gallic acid is renal protective in long term treatment of chronic kidney disease[J]. Clin Nutr, 2012, 31(3): 405-414.

[47] Yin JN, Jiang J, Wang HJ, et al. Protective effects of specneuzhenide on renal injury in rats with diabetic nephropathy[J]. Open Med (Wars), 2019, 14: 740-747.

[48] Liu BH, Lin J, Bai LX, et al. Paeoniflorin inhibits mesangial cell proliferation and inflammatory response in rats with mesangial proliferative glomerulonephritis through PI3K/AKT/GSK-3β pathway[J]. Front Pharmacol, 2019, 10: 978.

[49] Yu HY, Wang Y, He ZD, et al. Albiflorin ameliorates mesangial proliferative glomerulonephritis by PI3K/AKT/NF-κB pathway[J]. Hum Exp Toxicol, 2023, 42: 9603271221145386.

[50] Chen Y, Zhu ZP, Chen J, et al. Terpenoids from Curcumae Rhizoma : their anticancer effects and clinical uses on combination and versus drug therapies[J]. Biomed Pharmacother, 2021, 138: 111350.

[51] Giddings JC. Two dimensional separations: concept and promise[J]. Anal Chem, 1984, 56(12): 1258A-1270A.

[52] Qiu S, Yang WZ, Shi XJ, et al. A green protocol for efficient discovery of novel natural compounds: characterization of new ginsenosides from the stems and leaves of Panax ginseng as a case study[J]. Anal Chim Acta, 2015, 893: 65-76.

[53] Zhou WJ, Guo ZM, Yu L, et al. On-line comprehensive two-dimensional liquid chromatography tandem mass spectrometry for the analysis of Curcuma kwangsiensis[J]. Talanta, 2018, 186: 73-79.

[54] Wang M, Xu XY, Wang HD, et al. A multi-dimensional liquid chromatography/high-resolution mass spectrometry approach combined with computational data processing for the comprehensive characterization of the multicomponents from Cuscuta chinensis[J]. J Chromatogr A, 2022, 1675: 463162.

[55] Kruve A. Strategies for drawing quantitative conclusions from nontargeted liquid chromatography-high-resolution mass spectrometry analysis[J]. Anal Chem, 2020, 92(7): 4691-4699.

[56] Allen F, Pon A, Greiner R, et al. Computational prediction of electron ionization mass spectra to assist in GC/MS compound identification[J]. Anal Chem, 2016, 88(15): 7689-7697.

Funding

National Natural Science Foundation of China(82192912)

National Natural Science Foundation of China(82074273)

Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(ZYYCXTD-C-202009)

Program of State Key Laboratory of Drug Research(SIMM2103ZZ-06)